IRCCS Neuromed, Pozzilli, Italy.
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Eur J Clin Invest. 2024 Aug;54(8):e14199. doi: 10.1111/eci.14199. Epub 2024 Mar 26.
Defects of mitophagy, the selective form of autophagy for mitochondria, are commonly observed in several cardiovascular diseases and represent the main cause of mitochondrial dysfunction. For this reason, mitophagy has emerged as a novel and potential therapeutic target.
In this review, we discuss current evidence about the biological significance of mitophagy in relevant preclinical models of cardiac and vascular diseases, such as heart failure, ischemia/reperfusion injury, metabolic cardiomyopathy and atherosclerosis.
Multiple studies have shown that cardiac and vascular mitophagy is an adaptive mechanism in response to stress, contributing to cardiovascular homeostasis. Mitophagy defects lead to cell death, ultimately impairing cardiac and vascular function, whereas restoration of mitophagy by specific compounds delays disease progression.
Despite previous efforts, the molecular mechanisms underlying mitophagy activation in response to stress are not fully characterized. A comprehensive understanding of different forms of mitophagy active in the cardiovascular system is extremely important for the development of new drugs targeting this process. Human studies evaluating mitophagy abnormalities in patients at high cardiovascular risk also represent a future challenge.
线粒体自噬(mitophagy)是一种选择性的自噬形式,其缺陷在几种心血管疾病中普遍存在,是线粒体功能障碍的主要原因。因此,线粒体自噬已成为一种新的有潜力的治疗靶点。
在这篇综述中,我们讨论了线粒体自噬在心力衰竭、缺血/再灌注损伤、代谢性心肌病和动脉粥样硬化等相关心血管疾病的临床前模型中的生物学意义的现有证据。
多项研究表明,心脏和血管的线粒体自噬是一种应对压力的适应性机制,有助于心血管稳态。线粒体自噬缺陷会导致细胞死亡,最终损害心脏和血管功能,而通过特定化合物恢复线粒体自噬则可延缓疾病进展。
尽管已经进行了先前的努力,但对于应激反应中线粒体自噬激活的分子机制仍未完全阐明。全面了解心血管系统中不同形式的线粒体自噬对于靶向该过程的新药开发非常重要。评估高心血管风险患者线粒体自噬异常的人体研究也是未来的挑战。